Phaseline

Companies › Eisai

Eisai: clinical trials, targets and expected readouts

14 active drug programs in 37 registered trials: 13 Phase 1, 13 Phase 2, 7 Phase 3, 4 Phase 4; Oncology, Neurology, Immunology, Other; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Filgotinib Maleate
Tyrosine-protein kinase JAK1 inhibitor; Tyrosine-protein kinase JAK2 inhibitor; Tyrosine-protein kinase TYK2 inhibitor
JAK1, JAK2, TYK2, JAK3Phase 4Ulcerative ColitisNov 2027
Lecanemab (BAN2401)
Amyloid-beta A4 protein inhibitor
APPPhase 3Early Alzheimer's Disease; Preclinical Alzheimer's Disease; Alzheimer's Disease; Alzheimer's Disease(AD) …Dec 2026
Everolimus
FK506-binding protein 1A inhibitor
FKBP1APhase 3Renal Cell CarcinomaMar 2027
E2086–Phase 2Narcolepsy; Healthy VolunteersNov 2026
E2814
Anti-tau monoclonal antibody
–Phase 2Alzheimer's Disease; Alzheimers DiseaseDec 2026
Perampanel
Glutamate receptor ionotropic AMPA antagonist
GRIA4, GRIA3, GRIA2, GRIA1Phase 2Pediatric Epileptic Syndrome; Depressive Disorder; Depression; Depressive Disorder, MajorApr 2027
E6742–Phase 2Systemic Lupus ErythematosusAug 2028
E7386–Phase 1Advanced Neoplasms; Endometrial NeoplasmsMar 2027
E7386–Phase 1Solid NeoplasmsMar 2027
Eribulin (E7389)
Tubulin inhibitor
TubulinPhase 1Solid Tumor; Solid Neoplasms; Breast Neoplasms; Breast Cancer Stage IV …Mar 2027
H3B-6545
Estrogen receptor degrader (PROTAC)
–Phase 1Receptors, EstrogenMar 2027
E1018–Phase 1MalariaJul 2027
E-7090 (E7090)
Fibroblast growth factor receptor 1 inhibitor; Fibroblast growth factor receptor 2 inhibitor; Fibroblast growth factor receptor 3 inhibitor
FGFR1, FGFR2, FGFR3Phase 1Hepatic ImpairmentAug 2027
Farletuzumab
Folate receptor alpha inhibitor
FOLR1Phase 1Solid TumorAug 2030

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07034222Lecanemab (BAN2401)Phase 4Alzheimer's Disease(AD)NeurologyJan 2026
NCT06530732Lecanemab (BAN2401)Phase 3Alzheimer's DiseaseNeurologyJun 2026
NCT07766369E2086Phase 1Healthy VolunteersOtherNov 2026
NCT06602258Lecanemab (BAN2401)Phase 2Alzheimer's DiseaseNeurologyDec 2026
NCT06602258E2814Phase 2Alzheimer's DiseaseNeurologyDec 2026
NCT02623972Eribulin (E7389)Phase 2Inflammatory Breast CancerOncologyDec 2026
NCT03887455Lecanemab (BAN2401)Phase 3Early Alzheimer's DiseaseNeurologyDec 2026
NCT03973268PerampanelPhase 1DepressionPsychiatryFeb 2027
NCT07493265E2086Phase 2NarcolepsyNeurologyFeb 2027
NCT04288089H3B-6545Phase 1Receptors, EstrogenOncologyMar 2027
NCT02811861EverolimusPhase 3Renal Cell CarcinomaOncologyMar 2027
NCT03264664E7386Phase 1Advanced NeoplasmsOncologyMar 2027
NCT04008797E7386Phase 1Endometrial NeoplasmsOncologyMar 2027
NCT03833700E7386Phase 1Solid NeoplasmsOncologyMar 2027
NCT03207672Eribulin (E7389)Phase 1Solid TumorOncologyMar 2027
NCT04078295Eribulin (E7389)Phase 1Solid NeoplasmsOncologyMar 2027
NCT04015141PerampanelPhase 2Pediatric Epileptic SyndromeNeurologyApr 2027
NCT06854042E1018Phase 1MalariaInfectious diseaseJul 2027
NCT07088263Eribulin (E7389)Phase 3Breast NeoplasmsOncologyJul 2027
NCT04271488E-7090 (E7090)Phase 1Hepatic ImpairmentGastroenterologyAug 2027
NCT06964113Filgotinib MaleatePhase 4Ulcerative ColitisImmunologyNov 2027
NCT07604896Lecanemab (BAN2401)Phase 4Alzheimer s DiseaseNeurologyDec 2027
NCT01760005Lecanemab (BAN2401)Phase 2Alzheimers DiseaseNeurologyApr 2028
NCT05269394Lecanemab (BAN2401)Phase 2Alzheimers DiseaseNeurologyApr 2028
NCT01760005E2814Phase 2Alzheimers DiseaseNeurologyApr 2028
NCT05269394E2814Phase 2Alzheimers DiseaseNeurologyApr 2028
NCT04986579Eribulin (E7389)Phase 2Metastatic Breast CancerOncologyJun 2028
NCT07515014E6742Phase 2Systemic Lupus ErythematosusImmunologyAug 2028
NCT04468659Lecanemab (BAN2401)Phase 3Preclinical Alzheimer's DiseaseNeurologyDec 2028
NCT06889688Eribulin (E7389)Phase 3Breast Cancer Stage IVOncologyDec 2028
NCT07688460Lecanemab (BAN2401)Phase 4Alzheimer DiseaseNeurologyMar 2029
NCT07520760Eribulin (E7389)Phase 2HER 2 Negative Breast CancerOncologyApr 2030
NCT06384573Lecanemab (BAN2401)Phase 3Alzheimer's DiseaseNeurologyJun 2030
NCT04300556FarletuzumabPhase 1Solid TumorOncologyAug 2030
NCT06957431Eribulin (E7389)Phase 1Advanced LeiomyosarcomaOncologyMay 2031
NCT05915013PerampanelPhase 1Depressive Disorder, MajorPsychiatryDec 2032
NCT05786066PerampanelPhase 2Depressive DisorderPsychiatryMar 2033

Targets

FKBP1A (1) APP (1) JAK1 (1) JAK2 (1) TYK2 (1) JAK3 (1) GRIA4 (1) GRIA3 (1) GRIA2 (1) GRIA1 (1) FOLR1 (1) Tubulin (1)

Companies with the same targets

AbbVie Pfizer Incyte Sun Pharmaceutical Industries Alfasigma Takeda LEO Pharma Eli Lilly Suzhou Zelgen Biopharmaceuticals Alnylam Pharmaceuticals

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.